TROSPAS 15 MG

País: Israel

Idioma: inglés

Fuente: Ministry of Health

Cómpralo ahora

Ingredientes activos:

TROSPIUM CHLORIDE

Disponible desde:

CTS CHEMICAL INDUSTRIES LTD, ISRAEL

Código ATC:

G04BD09

formulario farmacéutico:

FILM COATED TABLETS

Composición:

TROSPIUM CHLORIDE 15 MG

Vía de administración:

PER OS

tipo de receta:

Required

Fabricado por:

CTS CHEMICAL INDUSTRIES LTD, ISRAEL

Área terapéutica:

TROSPIUM

indicaciones terapéuticas:

For the treatment of vegetative bladder dysfunction accompanied by urgency and/or frequency and/or urinary incontinence.

Fecha de autorización:

2022-12-31

Información para el usuario

                                PATIENT LEAFLET IN ACCORDANCE
WITH THE PHARMACISTS’ REGULATIONS
(PREPARATIONS) – 1986
THE MEDICINE IS DISPENSED WITH A DOCTOR'S PRESCRIPTION
ONLY
TROSPAS 15 MG
TROSPAS 30 MG
TABLETS
THE ACTIVE INGREDIENT AND ITS QUANTITY:
Trospium Chloride 15 mg
Trospium Chloride 30 mg
For a list of inactive ingredients and allergens in the
preparation see section 6.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THE
MEDICINE. This leaflet contains concise information about
the medicine. If you have any other questions, refer to the
doctor or the pharmacist.
This medicine has been prescribed for you. Do not pass it
on to others. It may harm them even if it seems to you that
their medical condition is similar.
THIS MEDICINE IS INTENDED FOR ADULTS AND CHILDREN
ABOVE 12 YEARS OF AGE.
1. WHAT IS THE MEDICINE INTENDED FOR?
This medicine is used for treatment of impaired function
of the urinary bladder, manifested by urgency and/or
frequency and/or urinary incontinence.
THERAPEUTIC GROUP: anticholinergic, antimuscarinic.
2. BEFORE USING THE MEDICINE: DO NOT USE THIS MEDICINE IF:
• You are sensitive (allergic) to the active ingredient
or to any of the other ingredients this medicine
contains (see section 6 – additional information).
You are suffering from:
• Urinary retention (urination is less frequent than
usual).
• Narrow-angle glaucoma.
• Arrhythmia (rapid and irregular heartbeat).
• Myasthenia gravis.
• Severe chronic inflammatory bowel disease
(Crohn’s disease, ulcerative colitis).
• Toxic megacolon.
• Renal disease requiring dialysis (creatinine
clearance <
10 ml/min/1.73 m
2
).
SPECIAL WARNINGS REGARDING THE USE OF THE MEDICINE BEFORE STARTING TREATMENT WITH TROSPAS TELL THE DOCTOR
IF YOU ARE SUFFERING OR HAVE SUFFERED IN THE PAST FROM:
• An obstruction in the digestive system (e.g. due to
narrowing of the pylorus - pyloric stenosis).
• Urine outflow obstruction or disturbance that may cause
residual urine.
• Hiatus hernia with an inflammation of the esophagus.
• Disorders of the autonomic nervous
                                
                                Leer el documento completo
                                
                            

Documentos en otros idiomas

Información para el usuario Información para el usuario árabe 06-03-2022
Información para el usuario Información para el usuario hebreo 06-03-2022

Buscar alertas relacionadas con este producto

Ver historial de documentos